Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
← catalyst calendarNCT06600724 · readout ≤ 11 d
Sponsored by MiMedx Group, Inc. (industry) · MDXG — their whole pipeline →. With SerenaGroup, Inc..
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
170estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-27 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-09-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetic Foot Ulcer
- Diabetic Foot
- Foot Ulcer Due to Type 2 Diabetes Mellitus
- Foot Ulcer, Diabetic
- Foot Ulcer
Interventions
- Other: Standard of Care
- Other: EPIEFFECT
- Other: EPIXPRESS
Primary outcome
what the primary-completion date above is the date OFPercentage of target ulcers achieving wound closure
measured 1 - 12 weeks
Permalink · MDXG's whole pipeline · Catalyst calendar · Every registered study · What changed